1
Hedner Ulla Karin Elisabeth: Compositions and methods for the treatment of bleeding disorders.. Novo Industri, June 10, 1987: EP0225160-A2 (26 worldwide citation)

A method for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, as well as a novel composition for use in treating bleeding disorders are disclosed.The method includes administering to a patient a composition comprising an effecti ...


2
Petersen Lars Christian, Hedner Ulla, Roejkjaer Rasmus: Pharmaceutical composition comprising a factor viia and a factor xiii. Novo Nordisk Health Care, November 9, 2005: EP1593389-A1 (10 worldwide citation)

The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.


3
Petersen Lars Christian, Hedner Ulla, Rojkjaer Rasmus: Use of pharmaceutical composition comprising a factor viia and a factor xiii. Novo Nordisk, February 12, 2003: EP1282438-A1 (3 worldwide citation)

The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.


4

5
Nordfang Ole, Hedner Ulla, Møller Niels Peter Hundahl: Pharmaceutical preparation for the treatment of prolonged coagulation time. Novo Nordisk, Nordfang Ole, Hedner Ulla, Møller Niels Peter Hundahl, NOVO NORDISK, May 14, 1992: WO/1992/007584 (2 worldwide citation)

A pharmaceutical preparation which, as an active component contains an agent that will block EPI activity (EPI inhibitor), is useful in the treatment of patients with prolonged coagulation time.


6
Petersen Lars Christian, Hart Charles E, Hedner Ulla, Rasmussen Mirella Ezban: Modified factor vii. Novo Nordisk, Zymogenetics, NOVO NORDISK, December 18, 1997: WO/1997/047651 (2 worldwide citation)

The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified ...


7
Nordfang Ole, Hedner Ulla, Moller Niels Peter Hundahl: Pharmaceutical preparation for the treatment of prolonged coagulation time.. Novonordisk, September 8, 1993: EP0558529-A1 (1 worldwide citation)

A pharmaceutical preparation which, as an active component contains an agent that will block EPI activity (EPI inhibitor), is useful in the treatment of patients with prolonged coagulation time.


8
Berkner Kathleen L, Petersen Lars Christian, Hart Charles E, Hedner Ulla, Bregengaard Claus: Modified factor vii. Zymogenetics, Novonordisk, August 20, 1997: EP0789759-A1

The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat ...


9
Hedner Ulla Karin Elisabeth: Composes et methodes pour le traitement des hemorragies, Compositions and methods for the treatment of bleeding disorders. Novo Nordisk Health Care, MCCARTHY TETRAULT, March 19, 1991: CA1281647

ABSTRACT A method for treating patients suffering frombleeding disorders not caused by clotting factor defects orclotting factor inhibitors, as well as a novel compositionfor use in treating bleeding disorders are disclosed. Themethod includes administering to a patient a compositioncomprising an ef ...


10
Knudsen Jens Bjerre, Hedner Ulla, Rojkjaer Rasmus: Combined use of factor vii polypeptides and factor ix polypeptides. Novo Nordisk Health Care, November 12, 2003: EP1359935-A1

The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide f ...